Arvelle Therapeutics wins Series A Finance Raise of the Year Award
Zug, Switzerland, November 20, 2019 – Arvelle Therapeutics GmbH, an emerging biopharmaceutical company focused on bringing innovative treatments to…
Zug, Switzerland, November 20, 2019 – Arvelle Therapeutics GmbH, an emerging biopharmaceutical company focused on bringing innovative treatments to…
Cenobamate significantly reduced focal seizure frequency, with as many as 20% of patients reaching zero seizures during the study’s maintenance…
Appoints Petra Molan as Senior Vice President Commercial and Enrico Dolfini as Vice President Legal Counsel Full leadership team now in place ahead…
Arvelle Therapeutics GmbH to provide SK Biopharmaceuticals an upfront payment of $100 million with future milestone potential of up to $430 million A…
Contact us using the form below (*Required fields) or on info@arvelletx.com